IRF8-mutant B cell lymphoma evades immunity through a CD74-dependent deregulation of antigen processing and presentation in MHCII complexes
Science Advances · 2024
DOI: 10.1126/sciadv.adk2091 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2024. Verfasst von Zhijun Qiu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Medical Oncology, Department of Medicine, Mays Cancer Center, University of Texas Health Science Center San Antonio, San A…. Hauptthemen laut MEDLINE: Interferon Regulatory Factors, Antigen Presentation, Mutation, Histocompatibility Antigens Class II. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
The mechanism by which interferon regulatory factor 8 (IRF8) mutation contributes to lymphomagenesis is unknown. We modeled IRF8 variants in B cell lymphomas and found that they affected the expression of regulators of antigen presentation. Expression of IRF8 mutants in murine B cell lymphomas suppressed CD4, but not CD8, activation elicited by antigen presentation and downmodulated CD74 and human leukocyte antigen (HLA) DM, intracellular regulators of antigen peptide processing/loading in the major histocompatibility complex (MHC) II. Concordantly, mutant IRF8 bound less efficiently to the promoters of these genes. Mice harboring IRF8 mutant lymphomas displayed higher tumor burden and remodeling of the tumor microenvironment, typified by depletion of CD4, CD8, and natural killer cells, increase in regulatory T cells and T follicular helper cells. Deconvolution of bulk RNA sequencing data from IRF8-mutant human diffuse large B cell lymphoma (DLBCL) recapitulated part of the immune remodeling detected in mice. We concluded that IRF8 mutations contribute to DLBCL biology by facilitating immune escape.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Medical Oncology, Department of Medicine, Mays Cancer Center, University of Texas Health Science Center San Antonio, San Antonio, TX 78229, USA.
- Department of Pathology, University of Texas Health Science Center San Antonio, San Antonio, TX 78229, USA.
- Department of Molecular Medicine, University of Texas Health Science Center San Antonio, San Antonio, TX 78229, USA.
- Department of Biochemistry and Structural Biology, University of Texas Health Science Center San Antonio, San Antonio, TX 78229, USA.
- South Texas Veterans Health Care System, Audie Murphy VA Hospital, San Antonio, TX 78229, USA.
ORCID-Profile: Zhijun Qiu, Purushoth Ethiraj, Lilly Chiou, Gabriela Huelgas-Morales, Zhao Zhang, Zhijie Liu, Yogesh K Gupta, Patricia L M Dahia, Ricardo C T Aguiar
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- NIAID NIH HHS
- BLRD VA
- NIEHS NIH HHS
Zitieren
APA
Qiu, Z., Khalife, J., Ethiraj, P., Jaafar, C., Lin, A. P., Holder, K. N., Ritter, J. P., Chiou, L., Huelgas-Morales, G., Aslam, S., Zhang, Z., Liu, Z., Arya, S., Gupta, Y. K., Dahia, P. L. M., & Aguiar, R. C. T. (2024). IRF8-mutant B cell lymphoma evades immunity through a CD74-dependent deregulation of antigen processing and presentation in MHCII complexes. Science Advances. https://doi.org/10.1126/sciadv.adk2091
Vancouver
Qiu Z, Khalife J, Ethiraj P, Jaafar C, Lin AP, Holder KN, et al. IRF8-mutant B cell lymphoma evades immunity through a CD74-dependent deregulation of antigen processing and presentation in MHCII complexes. Science Advances. 2024. doi:10.1126/sciadv.adk2091
BibTeX
@article{Qiu2024,
author = {Qiu, Zhijun and Khalife, Jihane and Ethiraj, Purushoth and Jaafar, Carine and Lin, An-Ping and Holder, Kenneth N and Ritter, Jacob P and Chiou, Lilly and Huelgas-Morales, Gabriela and Aslam, Sadia and Zhang, Zhao and Liu, Zhijie and Arya, Shailee and Gupta, Yogesh K and Dahia, Patricia L M and Aguiar, Ricardo C T},
title = {IRF8-mutant B cell lymphoma evades immunity through a CD74-dependent deregulation of antigen processing and presentation in MHCII complexes},
journal = {Science Advances},
year = {2024},
doi = {10.1126/sciadv.adk2091}
}
EUVIMED